Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA

Arthritis Rheum. 1981 Sep;24(9):1113-20. doi: 10.1002/art.1780240901.

Abstract

The effect of plasmapheresis in 8 patients with systemic lupus erythematosus (SLE) was investigated. Drug treatment was maintained at a constant level for at least 4 weeks before plasmapheresis. Levels of immune complexes were measured by a Raji cell radioimmunoassay, and by a solid-phase C1q-binding assay. Antibodies to ds-DNA and ss-DNA were measured by the Farr assay. In all cases, immune complexes and antibodies were lowered by plasmapheresis. In 5 patients, plasmapheresis was followed by a rapid rebound of complexes and antibody to pretreatment levels. In 3 in whom plasmapheresis was followed by treatment with cyclophosphamide for 1 month, a sustained immunochemical and clinical improvement followed, lasting in 2 cases for up to 3 years.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Antinuclear / analysis*
  • Antigen-Antibody Complex / analysis*
  • Arthritis / drug therapy
  • Azathioprine / therapeutic use
  • Chloroquine / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / therapy*
  • Middle Aged
  • Plasmapheresis*
  • Prednisone / therapeutic use

Substances

  • Antibodies, Antinuclear
  • Antigen-Antibody Complex
  • Chloroquine
  • Cyclophosphamide
  • Azathioprine
  • Prednisone